C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Increases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors boosted its stake in Eli Lilly and Company (NYSE:LLY) by 14.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,393 shares of the company’s stock after acquiring an additional 175 shares during the quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors’ holdings in Eli Lilly and Company were worth $1,234,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Capital Planning LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth $262,000. CHURCHILL MANAGEMENT Corp acquired a new position in shares of Eli Lilly and Company in the first quarter worth about $6,916,000. M&G Plc purchased a new position in Eli Lilly and Company in the first quarter valued at about $8,896,000. HighPoint Advisor Group LLC acquired a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $9,878,000. Finally, Leo Wealth LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth approximately $3,355,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.7 %

Shares of NYSE:LLY opened at $919.91 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The company’s 50-day moving average price is $904.41 and its 200 day moving average price is $850.31. The company has a market cap of $874.29 billion, a PE ratio of 135.48, a P/E/G ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Sell-side analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

LLY has been the subject of several research analyst reports. Truist Financial reiterated a “buy” rating and set a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Guggenheim raised their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Citigroup initiated coverage on shares of Eli Lilly and Company in a research report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.